Objective The Japan Respiratory Society documented a new category of guidelines for nursing and healthcare-associated pneumonia (NHCAP), which is distinct from community acquired pneumonia (CAP). The objective of this study was to determine the epidemiological differences between NHCAP patients in a teaching university hospital and a community hospital. In addition, to clarify the strategy for treatment of NHCAP, we investigated the role of atypical pathogens. Methods We analyzed 250 NHCAP and 421 CAP cases in a university hospital and 349 NHCAP and 374 CAP cases in a community hospital. Results Patient age and the incidences of poor general condition were significantly higher in the community hospital compared with those in the university hospital. The distribution and frequency of pathogens, especially multidrug-resistant (MDR) pathogens, were significantly different between the two hospitals. Central nervous system disorders, dementia and poor performance status, which was possibility related to aspiration pneumonia, were significantly more frequent in patients with NHCAP compared with those with CAP in both hospitals. Atypical pathogens were detected in a few cases in patients with NHCAP. Conclusion There were many differences in the clinical characteristics between NHCAP patients in a university hospital and a community hospital even for hospitals located in the same area. Aspiration pneumonia was thought to be the main characteristic of NHCAP in both hospitals. Thus, all NHCAP patients did not need the same empiric therapy with a multidrug regimen directed against MDR pathogens. In addition, physicians rarely need to consider atypical pathogens in NHCAP treatment.
Introduction
Healthcare-associated pneumonia (HCAP) is a new category that has been documented in the 2005 American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) guidelines (1) . Cases of HCAP substantially overlapped those of community-acquired pneumonia (CAP) because pneumonia developing outside of the hospital setting has traditionally been classified as CAP. However, HCAP is distinct from CAP because the epidemiologic pattern of HCAP is similar to that of hospital-acquired pneumonia (HAP), which has risk factors for multidrug-resistant (MDR) pathogens (2, 3) . The ATS/IDSA guidelines state that the patients with HCAP should receive empirical therapy directed against MDR-pathogens (2). Other reports have documented similar results about the epidemiology and treatment strategy of HCAP because the mortality rate was signifi-cantly higher among patients with HCAP compared with those with CAP (4-6). In contrast, Carratala et al. reported that the causative organisms of HCAP and CAP were very similar (7) . The British Thoracic Society guidelines have documented that patients with nursing home-acquired pneumonia (NHAP), which is usually categorized with HCAP, should be treated as having CAP, because there is no difference in the distribution of causative pathogens between patients with NHAP and other older adults with CAP (8, 9) . These differences in opinion are thought to be due to the heterogeneity of HCAP, including regional differences (differences in medical management and the healthcare systems between countries), and further evidence is necessary to clarify the differences between HCAP, CAP and HAP.
In 2011, the Japan Respiratory Society (JRS) Guidelines documented the new category, nursing and healthcareassociated pneumonia (NHCAP), which is distinct from CAP and is relevant to the Japanese population, healthcare insurance system, including the nursing-care insurance system, and the pattern of drug-resistant pathogens (10) . The objective of the present study was to determine the epidemiological differences between NHCAP patients in a teaching university hospital and those in a community hospital located in the same area. In particular, we focused on patient background, clinical characteristics, disease severity, the distribution of pathogens, antibiotic regimens and outcomes of patients with NHCAP. In addition, to clarify the strategy for the treatment of NHCAP, we investigated the role of atypical pathogens in these two different hospitals.
Materials and Methods

Study populations
All adult patients with pneumonia who were hospitalized or admitted to the Kawasaki Medical School Hospital (a 1182-bed teaching university hospital in Okayama, Japan) and the Kawasaki Hospital (a 293-bed community hospital in Okayama, Japan), from April 2005 to March 2011 were enrolled in this study. The diagnosis was based on clinical signs and symptoms (cough, fever, productive sputum, dyspnea, chest pain or abnormal breath sounds) and radiographic pulmonary abnormalities that were at least segmental and were as a result of pre-existing or other known causes. All cases of pneumonia occurring more than three days after hospitalization were considered nosocomial. Informed consent was obtained from all subjects and the study protocol was approved by the Ethics Committee at Kawasaki Medical School (approval number 468, clinical research for respiratory tract infections; approval number 679, clinical analysis for CAP, NHCAP, HCAP and HAP).
Definitions
NHCAP and CAP were defined according to the JRS guidelines (10) (11) (12) . NHCAP was determined in patients with any of the following: Group A) residence in a long-term nursing-home setting or healthcare home; Group B) discharge from hospital in the preceding 90 days; Group C) elderly persons or physically disabled persons who need healthcare; Group D) continuously receiving endovascular therapy in an ambulatory setting (including dialysis, antibiotics, anticancer drugs and immunosuppressants).
Patients with poor functional status were defined according to their performance status (PS) using the European Cooperative Oncology Group (ECOG) score (13) . ECOG grades are defined as follows; Grade 0: fully active, able to carry on all pre-disease performance without restriction; Grade 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; Grade 2: ambulatory and capable of all self-care but unable to carry out any work activity, up and about for more than 50% of working hours; Grade 3: capable of only limited self-care, confined to bed or chair for more than 50% of waking hours; Grade 4: completely disabled, unable to carry out any self-care, totally confined to bed or chair; Grade 5: death (13) .
Aspiration pneumonia was defined according to the Japanese Study Group on Aspiration Pulmonary Disease definition as pneumonia in a patient with a predisposition to aspiration because of dysphagia or swallowing disorders. Swallowing function was assessed using the water swallowing test, repetitive saliva swallowing test, simple-swallowing provocation test and video fluorography (12) . When swallowing function was not assessed using these examinations, the presence of overt symptoms of dysphagia or a medical history of aspiration was determined as a swallowing disorder in the patient.
Disease severity evaluation
The severity of pneumonia was assessed by the use of a clinical severity scale, the pneumonia severity index (PSI), published by the IDSA, which was calculated from data regarding age, complications, physical examination findings and laboratory data on admission (2) . Pneumonia severity was also evaluated using predictive rules according to the respective 5-point scoring systems for CAP and HAP in Japan proposed by the JRS: A-DROP (age, dehydration, respiratory failure, orientation disturbance and low blood pressure) (11) and I-ROAD (immunodeficiency, age, respiratory failure, orientation disturbance and dehydration) (12) .
Microbiological laboratory tests
Microbiological tests, such as Gram stain, cultures, urinary antigen tests and serological tests, were performed as described previously (14) (15) (16) . Blood cultures and nasopharyngeal swab specimens were obtained from all patients on admission for CAP and NHCAP and at the onset of pneumonia for HAP and, if pleural fluid and sputum were available, a Gram stain test and a quantitative culture were obtained. Sputum data were only evaluated when the Gram stain test revealed numerous leukocytes (>25 in a ×100 microscopic field) and few squamous epithelial cells (<10 in a ×100 microscopic field). Certain invasive methods, such as bronchoscopic examination, were employed to obtain specimens in some patients after full explanation of the procedures. These specimens were also used for culturing of Mycoplasma pneumoniae and Legionella species on pleuropneumonia-like organism broth (Difco, Detroit, MI, USA) and buffered charcoal-yeast extract alpha agar, respectively. Cultures for Chlamydophila pneumoniae and C. psittaci were performed using cycloheximide-treated HEp-2 cells grown in a 24-well cell culture plate (15) . All specimens were passaged twice. Culture confirmation was done by fluorescent-antibody staining with C. pneumoniae and C. psittaci species-specific and genus-specific monoclonal antibodies. Nasopharyngeal swab specimens were also tested for influenza A and B viruses using a direct enzyme immunoassay. Specimens were also used for polymerase chain reaction (PCR) of M. pneumoniae, Chlamydophila species and Legionella species. The target DNA sequences were a region of the 53-kDa gene for C. pneumoniae, the major outer membrane gene for Chlamydophila, the P1 cytadhesin gene for M. pneumoniae and the nucleotide sequence of the 5S-ribosomal DNA for Legionella (16) . These assays were performed as described previously (14, 16) .
Paired serum samples were collected at intervals of at least four weeks after onset. Complement fixation (CF) tests were done in all patients for antibodies to influenza A and B viruses, adenovirus, respiratory syncytial virus, cytomegalovirus and parainfluenza virus types 1, 2 and 3. Antibodies against M. pneumoniae were measured using a particle agglutination (PA) test (Serodia-Myco II kit, Fujirebio, Tokyo, Japan), Legionella species using a microagglutination test (detection of L. pneumophila serogroups 1-6, L. bozemanii, L. dumoffii, L. gormanii and L. micdadei), and Coxiella burnetii using an indirect immunofluorescence test. A microimmunofluorescence test was used for the titration of IgG and IgM antibodies against chlamydial species, using formalinized elementary bodies of C. pneumoniae KKpn-15, C. trachomatis L2/434/Bu and C. psittaci Budgerigar-1 strains as antigens (14) . Rheumatoid factors were absorbed with GullSORB (Meridian Bioscience Inc., Cincinnati, OH, USA) before IgM titrations. In addition to serology, culturing, and/ or PCR, a urinary antigen test (Binax NOW, Binax Inc. Portland, ME, USA) was used for the detection of S. pneumoniae and L. pneumophila.
Criteria for the determination of microbial etiology
The microbial etiology was classified as "definitive", "presumptive" or "unknown" as reported previously (14) (15) (16) . A definitive etiology was defined if one of the following conditions was present: 1) blood or pleural fluid cultures yield the presence of a bacterial or fungal pathogen; 2) urinary antigen test results are positive for L. pneumophila or S. pneumoniae; 3) respiratory specimens culture results positive for M. pneumoniae, C. psittaci or Legionella species; 4) nasopharyngeal antigen test results are positive for influenza A and B viruses; 5) a four-fold increase in the antibody titer for viruses, M. pneumoniae (to !1:160), Legionella species (to !1:128), C. burnetii or Chlamydia and Chlamydophila species (IgM or IgG); and 6) a single increase in the IgM titer for Chlamydia and Chlamydophila species of !1:32. A presumptive etiology was considered if any of the following conditions were present: 1) an organism show heavy (!10 7 cfu/mL) or moderate (10 6 cfu/mL) growth of a predominant bacterium on a sputum culture in combination with Gramstain findings; 2) any microorganism is isolated from bronchoscopic specimens when its concentration reaches !10 5 cfu/mL in quantitative culture; 3) an antibody titer for M. pneumoniae is !1:320 in either an acute-phase or convalescent-phase serum sample; 4) an antibody titer for Legionella species is !1:256 in either an acute-phase or convalescent-phase serum sample; or 5) respiratory specimen culture and PCR results are positive for C. pneumoniae.
Clinical outcome evaluation
Initial treatment failure, duration of antibiotic therapy, the length of hospital stay and survival were evaluated. Initial treatment failure was defined as when the patient died during the treatment or when the antibiotics had no effect and were switched to other antibiotics, or broad-spectrum antibiotics were added.
Statistical analysis
Statistical analysis was performed using Stat View version 5.0. (SAS Institute Inc, Cary, NC, USA). The incidence of clinical findings was analyzed using Fisher's Exact test. Continuous variables were compared using the Student's t test when variables were normally distributed and the MannWhitney U test when variables were non-normally distributed. Multiple logistic regression analysis was used to assess the role of several variables as risk factors for mortality. The contribution of each potential risk factor was denoted by an odds ratio (OR) and associated 95% confidence interval (CI).
Results
Patient characteristics
During the study period, we enrolled and analyzed 739 pneumonia cases in a university hospital and 812 pneumonia cases in a community hospital; of these, 250 (34%) and 349 (43%) cases were classified as NHCAP, respectively, and the proportion of NHCAP cases among pneumonia patients who required hospitalization was significantly higher in the community hospital compared with those in the university hospital (p=0.0003, Table 1 ). Among the NHCAP criteria, the background of patients clearly differed between the two hospitals (Table 1) . Patients with residence in a long-term nursing-home setting or healthcare home and elderly persons or physically disabled persons who need healthcare were more often seen in the community hospital.
The characteristics of NHCAP and CAP patients in both Table 2 . Patients with NHCAP were significantly older than those with CAP (p<0.0001), but the male/female ratio did not differ between the two groups in either hospital (Table 2) . Among co-morbid conditions, cerebrovascular disease was significantly more frequent in patients with NHCAP compared with those with CAP in both hospitals ( Table 2 , p<0.0001). Among general conditions, patients with poor functional status (PS grade 3 and 4), dementia, receiving tube feeding and aspiration were significantly greater in NHCAP than in CAP in both hospitals (Table 2, p<0.0001). Several differences were observed between NHCAP patients in the university and community hospitals. NHCAP patients in the community hospital were significantly older than those in the university hospital (p<0.0001). The incidences of co-morbid illness (chronic heart disease p<0.0001, cerebrovascular disease p=0.0122 and neoplastic disease p= 0.0469) and poor general condition (poor PS p=0.0345, dementia p<0.0001, receiving tube feeding p=0.0469 and aspiration p=0.0266) were significantly higher in the community hospital compared with those in the university hospital.
Pneumonia severity
The severity of NHCAP and CAP was assessed by means of the PSI criteria from the IDSA/ATS and A-DROP and I-ROAD systems of the JRS ( Universityhospital Communityhospital Pathogens 0.0001). The average A-DROP and I-ROAD scores in patients with NHCAP was also significantly higher compared to those of patients with CAP in both hospitals (p<0.0001).
No differences in pneumonia severity were observed between the two hospitals.
Pathogen distribution
Details of the microorganisms identified in the NHCAP and CAP patients in both hospitals are shown in Table 4 . Among CAP patients, S. pneumoniae, M. pneumoniae and Haemophilus influenzae were the leading pathogens in both hospitals. In contrast, among NHCAP patients, the most common pathogens were Staphylococcus aureus (21%) followed by S. pneumoniae (20%), Klebsiella species (10%) and Pseudomonas aeruginosa (9%) in patients in the university hospital, and S. pneumoniae (9%) followed by S. aureus (8%), Klebsiella species (8%) and H. influenzae (7%) in patients in the community hospital. The distribution and frequency of pathogens were significantly different between the two hospitals with S. pneumoniae (p=0.0002), P. aeruginosa (p<0.0001) and S. aureus (p<0.0001). P. aeruginosa, which has a potential for antibiotic resistance (MDR-pathogens), was isolated frequently from patients with NHCAP in the university hospital (p=0.0001), but the frequency of P. aeruginosa was not different between CAP and NHCAP in the community hospital (p>0.9999). The frequency of another MDR-pathogen, methicillin-resistant S. aureus (MRSA), was also significantly different between the two hospitals (p=0.0003).
Among the atypical pathogens, C. pneumoniae, M. pneu- B moniae and Legionella species were detected more frequently in patients with CAP than in patients with NHCAP (Fig. 1) . However, during our study period, an outbreak of C. pneumoniae occurred among residents in the healthcare home and the difference was not significant between CAP and NHCAP in the community hospital (p=0.1790).
Clinical outcomes
Initial antibiotics were prescribed according to the JRS CAP guideline (11) . Most commonly, NHCAP and CAP patients received antibiotic monotherapy, mainly using β-lactams (university hospital, NHCAP 85% versus CAP 90%, p=0.1686; community hospital, NHCAP 85% versus CAP 90%, p=0.0892). Rates of initial treatment failure and inhospital mortality were higher in NHCAP patients compared with CAP patients (Table 5) . In NHCAP patients, these rates were higher in the community hospital compared with the university hospital, respectively, but these differences did not reach statistical significance (initial treatment failure, university hospital 27% versus community hospital 31%, p= 0.1725; in-hospital mortality, university hospital 10% versus community hospital 14%, p=0.2111). The duration of antibiotic therapy and hospital stay were longer in NHCAP patients in the community hospital compared with NHCAP patients in the university hospital.
Risk factors for mortality in patients with NHCAP
In an analysis to assess the relationship between risk factors and mortality in NHCAP patients, we calculated OR and the associated 95% CI (Table 6) . High score for A-DROP (university hospital, OR 2.94, 95% CI 1.49-6.77, p= 0.012; community hospital, OR 3.15, 95% CI 1.41-7.22, p= 0.005), low levels of serum albumin (university hospital, OR 0.11, 95% CI 0.02-0.61, p=0.018; community hospital, OR 0.21, 95% CI 0.01-0.71, p=0.022) and high score for PS (university hospital, OR 2.18, 95% CI 1.34-5.12, p=0.033; community hospital, OR 2.01, 95% CI 1.11-4.51, p=0.041) were a risk factor for mortality in both hospitals. Co-morbid conditions* Chronic lung disease 61 (35) 52 (31) 117 (32) 22 (27) Chronic heart disease 32 (18) 17 (10) 69 (19) 8 (10) Cerebrovascular disease 68 (39) 26 (15) 124 (35) 2 (2) Diabetes mellitus 18 (10) 16 (9) 38 (10) 7 (8) Neoplastic disease 27 (15) 17 (10) 59 (16) 12 (15) Dementia 100 (58) 30 (18) 215 (60) 3 (4) Receiving tube feeding 44 (25) 11 (6) 65 (18) 
Differences in clinical characteristics among NHCAP patients
The characteristics of NHCAP patients in the four groups are shown in Table 7 . Several differences were observed among the four NHCAP groups. NHCAP patients of groups A and C were significantly older than those in patients of groups B and D (p<0.0001). The incidences of co-morbid illness (chronic heart disease and cerebrovascular disease) and poor general condition (dementia, receiving tube feeding and aspiration) were significantly higher in patients of groups A and C compared with those in patients of groups B and D (p<0.0001). S. pneumoniae was more often seen in patients of groups B and D compared with the groups A and C, but these differences did not reach statistical significance. The distribution and frequency of other pathogens were not different among the four NHCAP groups. Rates of inhospital mortality were higher in patients of groups A and C compared with patients of groups B and D, but these differences did not reach statistical significance.
Discussion
NHCAP was newly identified as a distinct condition by the JRS in 2011, and which is separate from HCAP (ATS/ IDSA) in terms of the Japanese population, healthcare insurance system, including the nursing-care insurance system, and the pattern of drug-resistant pathogens (10) . The present results revealed differences in patient background, clinical characteristics, disease severity, distribution of pathogens and clinical outcome between NHCAP and CAP. These differences were similar to previous reports that investigated the differences in HCAP and CAP (4) (5) (6) .
In this study, we clarified differences in clinical characteristics between NHCAP patients in a teaching university hospital and patients in a community hospital located in the same area. Our results demonstrated that there were many differences in the clinical characteristics between the two hospitals despite the recording of identical pneumonia severity. First, the background of patients with NHCAP clearly differed between the two hospitals. Second, the age of patients and the incidences of co-morbid illness (chronic heart diseases, cerebrovascular disease and neoplastic disease) and poor general conditions (poor PS, dementia, receiving tube feeding and aspiration) were significantly higher in the community hospital compared with those in the university hospital. Third, the distribution and frequency of pathogens, especially MDR-pathogens (P. aeruginosa and MRSA) were significantly different between the two hospitals. In particular, the frequency of P. aeruginosa was not different between CAP and NHCAP in the community hospital.
In an HCAP study, Watanabe et al. demonstrated that there were many differences in the clinical characteristics between the small hospital group and large hospital group, especially with regard to the severity of pneumonia (17) . These differences in clinical characteristics between the two hospitals might be because of differences in the proportion of elderly patients, the characteristics of each hospital and the local environment. In fact, Umeki et al demonstrated that the NHAP group was clinically different from the HCAP other than NHAP group, based on bacteriological examination and mortality rates (18) . The present results also demonstrated that there were several differences in the clinical characteristics among the patients in NHCAP groups (Table 7) . Thus, differences in clinical outcomes between the two hospitals also might be a result of the differences in the proportion of elderly patients. Among countries, there are marked differences in medical management and healthcare systems. Thus, NHCAP is thought to be heterogeneous not only between countries but also among hospitals located in the same area.
Recently, studies have cast doubt on the notion that all patients with HCAP must receive empirical therapy with a multidrug regimen directed against MDRpathogens (19, 20) . The present results support these previous reports because the association between the isolation of MDR-pathogens and mortality of NHCAP patients was not. Multidrug regimens directed against MDR-pathogens might have to be used only when the risk factors for MDRpathogens, such as the receipt of broad-spectrum antibiotics for >2 days within the previous 90 days and tube feeding, were present. In addition, our results together with previous reports (6, 21) indicate that aspiration because of silent aspiration is the most important mechanism for the pathogenesis of NHCAP (56% in the university hospital and 65% in the community hospital, p=0.0266). Central nervous system disorders, dementia and poor PS were significantly more frequent in patients with NHCAP compared with those with CAP in both hospitals. Previous studies (6, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) as well as in the current study suggested that a high frequency of aspiration pneumonia is possibility related to older age, poor PS, dementia and previous brain infarction in Japan. Anaerobes, Streptococcus anginosus group, S. pneumonia, H. influenzae and S. aureus, are thought to be important pathogens in aspiration pneumonia (12) . Thus, the JRS guidelines recommend the use of β-lactamase inhibitor penicillin combinations (sulbactam/ampicillin or tazobactam/piperacillin), β-lactams + clindamycin or carbapenems for the empirical therapy of NHCAP (10) .
In this study, we also focused on investigating the role of atypical pathogens in NHCAP patients. One of the most important differences between CAP and HAP is the prevalence of causative pathogens, such as atypical pathogens. In community setting, physicians have to consider the atypical pathogens M. pneumoniae, Legionella, C. pneumoniae and C. psittaci, for the selection of antibiotics (2, 11, 14) . Previous studies on HCAP investigated atypical pathogens using serology only (4) (5) (6) (7) 22) . In this study, we carried out culture, PCR and serology for the detection of atypical pathogens in all patients. All atypical pathogens were detected more frequently in patients with CAP than in patients with NHCAP. Our results together with those of previous studies (4-7) indicate that physicians may not need to consider atypical pathogens in NHCAP treatment with the exception of outbreaks. One study demonstrated a high frequency of C. pneumoniae infection in non-intubated patients with NHAP (22) . They speculated that one reason for the high frequency was an outbreak of C. pneumoniae infection in a nursing home. Outbreaks of C. pneumoniae in nursing homes and long-term care facilities reported in previous studies support this assumption (31, 32) . In fact, during our study period, an outbreak of C. pneumoniae occurred among residents in a care home.
In agreement with many prior studies (17, 19, 22, 30) , a high score for A-DROP, low levels of serum albumin and poor PS were associated with NHCAP mortality. Among the several co-morbid conditions, malnutrition is one of the most important factors that affects the prognosis apart from being a risk factor for pneumonia (33, 34) . It has been strongly suggested that a lower serum albumin level is a predictive factor for a poor prognosis in elderly patients (35, 36) . In addition, a lower serum albumin level is associated with advanced age and poor PS of patients with NHAP (22) . This simple marker should be measured for the management of NHCAP.
In the largest retrospective microbiological study in patients with HCAP, Kollef et al. reported that the most common pathogens were MRSA and P. aeruginosa (4). Micek et al. also reported that HCAP patients were significantly more likely than CAP patients to be infected with MRSA, P. aeruginosa and other gram-negative rods (5). In contrast, Carratala et al. found no significant difference in the causative organisms between HCAP and CAP patients (7) . In a Japanese retrospective observational study, Shindo et al. found that S. pneumoniae and S. aureus were the most frequently isolated pathogens in HCAP patients (6) . The present results were similar to those of Shindo's study, but the frequency of pathogens was significantly different between the two hospitals..
Our study had several limitations. First, the data were collected retrospectively from each hospital. Secondly, pathogens could not be identified in about half of NHCAP patients. Of particular note is that one-third of NHCAP patients had no sputum expectoration. Third, the swallowing function testing was not performed uniformly on all patients; it was performed on approximately 60% patients in the current study.
In conclusion, our results demonstrated that there were many differences in the clinical characteristics between NHCAP patients in a teaching university hospital and in a community hospital even when they were located in the same area. Aspiration pneumonia, including mainly silent aspiration, is thought to be the main characteristic of NHCAP in Japan. Our results showed that it was not necessary for NHCAP patients to be treated with combination therapy, including at least one drug that is active against MDR-pathogens, as recommended by ATS/IDSA. Our results also showed that physicians may not need to consider atypical pathogens in NHCAP treatment, with the exception of C. pneumoniae outbreaks.
